Komori
Governance4582SymBio Pharmaceuticals LimitedPharmaceuticals

Independent Officer Notification Form

As of 24 March 2026, 5 outside directors are scheduled to retire upon expiry of their terms, and 3 outside directors are scheduled to be newly appointed. Nomura Hiroshi (野村 博) will be additionally designated as an independent officer.

Worth reading
33Immaterial
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Number of independent officers2Number

This is the number of people reported to the exchange as independent officers. Whether someone is an outside officer and whether they qualify as independent are separate determinations.

Changes this time

Matsumoto Shigatoshi (松本 茂外志), Ebinuma Eiji (海老沼 英次), Watanabe Kiyoshi (渡部 潔), Imabeppu Toshio (今別府 敏雄) and Shibo Hiroshi (賜保 宏) are scheduled to retire upon expiry of their terms at the conclusion of the annual general meeting of shareholders to be held on 24 March 2026. Nomura Hiroshi (野村 博), Mizutani Eiji (水谷 英滋) and Ichinozawa Tsuyoshi (市野澤 剛士) are scheduled to be newly appointed as outside directors, and Nomura Hiroshi (野村 博) will be additionally designated as an independent officer.

Governance structure
ItemDetails
Number of independent officers2 (Nomura Hiroshi (野村 博) and Shimomura Koichi (下村 恒一))
Changes this timeMatsumoto Shigatoshi (松本 茂外志), Ebinuma Eiji (海老沼 英次), Watanabe Kiyoshi (渡部 潔), Imabeppu Toshio (今別府 敏雄) and Shibo Hiroshi (賜保 宏) are scheduled to retire upon expiry of their terms at the conclusion of the annual general meeting of shareholders to be held on 24 March 2026. Nomura Hiroshi (野村 博), Mizutani Eiji (水谷 英滋) and Ichinozawa Tsuyoshi (市野澤 剛士) are scheduled to be newly appointed as outside directors, and Nomura Hiroshi (野村 博) will be additionally designated as an independent officer.
Items this document does not state (6)
Corporate Governance StructureNumber of directorsCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To appoint new outside directors following the retirement of the current directors upon expiry of their terms, and to additionally designate Nomura Hiroshi (野村 博) as an independent officer.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Independent Officer Notification Form | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori